GTHX Insider Trading Activity and SEC Form 4 Filings
GTHX insider trading summary
No open-market insider purchases or sales of G1 Therapeutics, Inc. (GTHX) have been reported on SEC Form 4 in the past 12 months.
Latest GTHX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 5, 2024 | Mark Avagliano | Chief Business Officer | Sell | $7K (2,638 @ $2.51) |
| Jul 5, 2024 | John W. V Umstead | Chief Financial Officer | Sell | $1K (527 @ $2.51) |
| Jul 5, 2024 | Terry L Murdock | Chief Operating Officer | Sell | $6K (2,475 @ $2.51) |
| Jul 5, 2024 | John E. (Jack) Bailey Jr. | President and CEO | Sell | $19K (7,662 @ $2.51) |
| Jul 5, 2024 | Rajesh Malik | Chief Medical Officer | Sell | $6K (2,475 @ $2.51) |
| Jul 5, 2024 | Andrew Perry | Chief Commercial Officer | Sell | $3K (1,337 @ $2.51) |
| May 23, 2024 | Monica R. Thomas | Chief Legal & People Officer | Sell | $25K (5,826 @ $4.27) |
| May 13, 2024 | John W. V Umstead | Chief Financial Officer | Sell | $39K (8,151 @ $4.79) |
| May 13, 2024 | Mark Avagliano | Chief Business Officer | Sell | $39K (8,151 @ $4.79) |
| May 13, 2024 | Terry L Murdock | Chief Operating Officer | Sell | $39K (8,151 @ $4.79) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.